At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 3 enrolled
Drug / intervention
Imiquimod, 5% cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal
In Brief
A Phase 1 clinical trial evaluating 1064 nm Nd:YAG laser and Imiquimod, 5% cream for Healthy. Completed, enrolled 3 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy of tattoo removal using topical imiquimod, 5% cream in conjunction with the 1064nm Nd:YAG laser. This procedure for tattoo removal will be compared to a laser removal alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsGraceway Pharmaceuticals, LLC
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedMar 2008
Primary CompletionAug 2014
TodayJul 2026
First PostedMar 19, 2008
Enrollment StartFeb 1, 2008
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 18.3 years ago
Interventions
1064 nm Nd:YAG laserdevice
The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
Imiquimod, 5% creamdrug
2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month